Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

rediff.com - Anjali Singh - Indian Pharma Bets Beyond US Generics
Indian Pharma Bets Beyond US Generics
Rediff.com

Companies are investing heavily in complex injectables, respiratory therapies and biosimilars to improve margins and diversify portfolios. Indian pharmaceutical companies are increasingly shifting their growth focus beyond the traditional US…

seekingalpha.com - Petri Dish Reports - ARS Pharma: Strong Growth Meets A Coverage Wall (NASDAQ:SPRY)
ARS Pharma: Strong Growth Meets A Coverage Wall (NASDAQ:SPRY)
Seeking Alpha

ARS Pharmaceuticals is rated a hold due to heightened near-term execution risk despite a compelling long-term Neffy opportunity. SPRY's Q1 revenue nearly tripled to $22.7M, but aggressive SG&A spending drove a $60.6M net loss and elevated cash…

indianexpress.com - Parul Kulshrestha - 'Spurious' injections that 'contained no oxytocin': Rajasthan pharma distributor loses licence
'Spurious' injections that 'contained no oxytocin': Rajasthan pharma distributor loses licence
The Indian Express

Rajasthan's Drug Control Department has cancelled the wholesale drug licence of a pharma distributor operating out of Kota over the alleged sale of thousands of spurious oxytocin injections and other irregularities. The action comes amid heightened…

fool.com - Brendan Coffey - AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
The Motley Fool

Investors seeking reliable dividends often look to the healthcare sector, but choosing between AbbVie Inc (ABBV +3.72%) and Pfizer Inc (PFE 1.70%) requires a close look at their post-pandemic growth strategies and pipelines. AbbVie focuses on…

benzinga.com - Vandana Singh - Why Is Shuttle Pharma Stock Gaining Friday? - Shuttle Pharmaceuticals (NASDAQ:SHPH)
Why Is Shuttle Pharma Stock Gaining Friday? - Shuttle Pharmaceuticals (NASDAQ:SHPH)
Benzinga

The company said it is assessing behind-the-meter power generation assets in Idaho and Alberta as part of a strategy aimed at lowering operating costs and increasing flexibility for its growing mining business. United Dogecoin said the initiative…

thehindubusinessline.com - Government proposes simplified drug import rules to boost pharma R&D
Government proposes simplified drug import rules to boost pharma R&D
BusinessLine

In a significant step towards promoting research and innovation and enhancing ease of doing business in the pharmaceutical sector, the Union Ministry of Health and Family Welfare has proposed amendments to the Drugs Rules, 1945, to simplify the…

thehindubusinessline.com - Alembic Pharma gets USFDA final approval for Oseltamivir oral suspension
Alembic Pharma gets USFDA final approval for Oseltamivir oral suspension
BusinessLine

Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Oseltamivir Phosphate for Oral Suspension, 6 mg/mL. The approved ANDA is therapeutically…

thehindubusinessline.com - Zydus Lifesciences, Sunshine Healthcare form $20 million JV to set up pharma manufacturing facility in Sri Lanka
Zydus Lifesciences, Sunshine Healthcare form $20 million JV to set up pharma manufacturing facility in Sri Lanka
BusinessLine

Zydus Lifesciences and Sri Lanka's Sunshine Healthcare have formed a joint venture to establish a pharmaceutical manufacturing facility in Sri Lanka with an investment commitment of over $20 million, as the island nation looks to strengthen…

marketbeat.com - Royalty Pharma (NASDAQ:RPRX) EVP Sells 9,098 Shares
Royalty Pharma (NASDAQ:RPRX) EVP Sells 9,098 Shares
MarketBeat

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 9,098 shares of the stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $55.18, for a total transaction of $502,027.64. Following the…

marketbeat.com - Barton Investment Management Makes New Investment in Royalty Pharma PLC $RPRX
Barton Investment Management Makes New Investment in Royalty Pharma PLC $RPRX
MarketBeat

Barton Investment Management bought a new stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 18,875 shares of the…

thehindu.com - Saptaparno Ghosh - Latest LPG supply directives and what changes now | Explained
Latest LPG supply directives and what changes now | Explained
The Hindu

The story so far: In the first signs of easing pressure on liquified petroleum gas (LPG) with the probable culmination of the West Asia conflict, the Union Petroleum Ministry Thursday (June 25, 2026) restored commercial LPG supply to the pre-crisis…

newswire.ca - A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
CNW

Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed…

seekingalpha.com - Eduardo Salas - British American Tobacco Stock: Not Simply Philip Morris' Lagging Sibling (NYSE:BTI)
British American Tobacco Stock: Not Simply Philip Morris' Lagging Sibling (NYSE:BTI)
Seeking Alpha

British American Tobacco is rated as a Sell due to unclear growth in its Vapour and Heated Product segments, margin dilution, and regulatory headwinds despite a ~5.4% dividend yield. BTI's Modern Oral segment has shown strong growth and is…

newswire.ca - Lupin Receives Tentative Approval from U.S. FDA for Enzalutamide Tablets
Lupin Receives Tentative Approval from U.S. FDA for Enzalutamide Tablets
CNW

MUMBAI, India and NAPLES, Fla., June 26, 2026 /CNW/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received tentative approval from the United…

fool.com - Thomas Niel - An Analyst Just Declared Eli Lilly the 'Clear Winner' of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?
An Analyst Just Declared Eli Lilly the 'Clear Winner' of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?
The Motley Fool

In the eyes of Wall Street, Eli Lilly (LLY +2.19%) continues to cement its lead over the competition in the field of weight-loss and diabetes drugs. After revealing a pair of positive developments coinciding with the American Diabetes Association's…

Receive a Daily briefing on Pharma Industry News

Get Started